* Viragen Inc., of Miami, raised $3.5 million in a private placement of8.75 million restricted shares, which will remain locked up for six to 18months.The company, which is conducting Florida Investigational Studyprograms involving its Alpha Leukoferon for treatment of multiplesclerosis and HIV/AIDS, currently has about 20 million sharesoutstanding.* PerSeptive Biosystems Inc., of Cambridge, Mass., has arranged forthe sale of $25 million of 8.25 percent of convertible subordinatednotes due in 2001. The notes will be convertible into shares of commonstock at $13.80. The company has also granted to managers of theoffering an over-allotment option to purchase an additional $3.75million principal amount of the notes.* Immunex Corp., of Seattle, will present six papers at the InternationalSociety of Experimental Hematology conference in Minneapolis thisweek highlighting the potentially valuable activities of the Flt3 ligand(Flt3-L), a blood cell growth factor discovered and cloned at Immunex.In preclinical studies, Flt3-L was shown to stimulate stem cells anddemonstrated the ability to spur the growth of specific blood lineages,as well as working in synergy with other, narrow-purpose growthfactors.082294
(c) 1997 American Health Consultants. All rights reserved.